Total
0
Shares
NeonMind (CSE:NEON) CEO to speak at the Psychedelic, Therapeutics, & Drug Development Conference
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Robert Tessarolo will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference
  • The conference, to be held virtually from May 4-6, will unite the top business and academic leaders
  • Robert will be speaking on the use of psychedelics in treating obesity and eating disorders
  • NeonMind is currently advancing two psilocybin-based drug development programs aimed at treating obesity
  • NeonMind is engaged in the research and development of products to optimize human health and performance
  • NeonMind Biosciences (NEON) opened trading at C$0.23 per share

NeonMind Biosciences President & CEO will speak at the Psychedelic, Therapeutics, & Drug Development Conference.

He will be speaking on the use of psychedelics in treating obesity and eating disorders.

The conference, being held virtually from May 4-6, will unite the top business and academic leaders including Frederick Barrett, Ph.D., Assistant Professor of Psychiatry & Behavioral Sciences at Johns Hopkins School of Medicine, to discuss, analyze, and share intelligence on regulatory changes and other challenges on psychedelic research for the treatment of a myriad of serious chronic medical conditions.

"The Psychedelic, Therapeutics, and Drug Development Conference is an excellent opportunity for NeonMind to share our vision and progress with other industry leaders and key stakeholders," said Rob Tessarolo.

"I also look forward to listening to the many great experts and innovators who will discuss a number of regulatory and policy changes that will help unlock the full health potential of this emerging field."

NeonMind is currently advancing two psilocybin-based drug development programs aimed at treating obesity.

Psychedelic therapy has the potential to institute long-term positive behaviours that may aid in weight loss and its maintenance, and psilocybin in low doses may help control appetite and satiety.

"There is a clear need for new treatments, new solutions, new approaches for the obesity epidemic and psychedelics are well-positioned to offer new therapeutic breakthroughs," said Rob Tessarolo.

"NeonMind will continue to advance our important research and be a leader in commercialization following regulatory approval."

NeonMind is engaged in the research and development of products to optimize human health and performance.

NeonMind has two divisions, a pharmaceutical division engaged in drug development of psychedelic compounds, and a consumer products division with a focus on mushroom-infused products.

NeonMind Biosciences (NEON) opened trading at C$0.23 per share.

More From The Market Herald
Lobe Sciences (CSE:LOBE) to present at the Benzinga Global Small Cap Conference

" Lobe Sciences (CSE:LOBE) to take part in mental health conference

Lobe Sciences (LOBE) CEO Philip Young will participate in a round table discussion at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference.
Optimi Health (CSE:OPTI) multi-purpose mushroom facility advances completion and licensing

" Optimi Health (CSE:OPTI) updates build-out of mushroom production facility

Optimi Health (OPTI) is continuing to advance construction of its mushroom research and production facility in Princeton, British Columbia.
Canbud (CSE:CBDX) signs MOU for psilocybin producing mushroom R&D

" Canbud (CSE:CBDX) signs MOU for psilocybin producing mushroom R&D

Canbud Distribution (CBDX) has entered into a memorandum of understanding with the College of Agriculture, Science and Education (CASE).
Red Light Holland (CSE:TRIP) expands iMicrodose product offerings

" Red Light Holland (CSE:TRIP) expands iMicrodose product offerings

Red Light Holland (TRIP) is now offering iMicrodose All-In-One Mushroom Fruiting Extracts for sale across Europe.